Catalog
Synthetic Tβ4 active fragment

TB-500 (Thymosin β4 fragment)

Veterinary use exists; no FDA-approved human indication. Often co-marketed with BPC-157.

Research-only / unregulatedGrade D — Plausible, unprovenFDA Category 2 (2023) — barred from 503A compounding
Target
G-actin sequestration; ILK/Akt signaling

Mechanism of action

17-aa fragment of full Thymosin β4. Sequesters G-actin, modulates cell migration, angiogenesis, and inflammation.

Pharmacokinetics

SC/IM. Limited human PK data.

Clinical context

None FDA-approved. Used off-label for soft-tissue injury.

Safety

Contraindications
  • Active malignancy (theoretical)
Adverse effects
  • Largely unknown
  • Banned by WADA (S2 class)

Covered in modules

Module 06
BPC-157, TB-500 & 'Healing Peptides'
The grey-market repair narrative — what the rat data show, what humans don't have.

Related compounds

Synthetic pentadecapeptide (gastric origin)
BPC-157

Generate prescriber-grade deep dive

Pull in expanded mechanism, PK/PD, dosing strategies for special populations, drug interactions, monitoring cadence, head-to-head differentials, prescriber pearls, and patient FAQs for TB-500 (Thymosin β4 fragment).

Educational reference. Not medical advice. Always verify against current FDA labeling and local regulatory guidance before prescribing or counseling.